Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437132 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL4599274 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL3205240 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL3205062 | 0.96 | ACE (0.52) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL20946311 | 0.96 | ACE (0.52) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL3204577 | 0.96 | ACE (0.52) | MDM2MDM4TP53ACEPTPN1 | |
| SCHEMBL23042775 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS | |
| SCHEMBL30441027 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS | |
| SCHEMBL30441164 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS | |
| SCHEMBL23042774 | 0.92 | ACE (0.49) | MDM2MDM4TP53ACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-10-23 | — | — | US | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-20240360178-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RAMBAM MED-TECH LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-11566057-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-01-31 | — | — | US | disclosed |
| US-7374898-B2 | Peptide inhibitors against seprase | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1919866-A2 | SUBSTITUTED INDOLES AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-20060172938-A1 | Peptide inhibitors against seprase | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2006-08-03 | — | — | US | disclosed |
| WO-2006042282-A2 | PEPTIDE INHIBITORS AGAINST SEPRASE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060062797-A1 | Novel materials and methods for the treatment of Alzheimer's disease patients | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT STONY BROOK | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330064-A1 | TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE | RPTOR, PSMG3, MTOR | MDM2 86/4885MDM4 1267/4885TP53 106/4885 |
| US-20070043101-A1 | Substituted indoles and methods of their use | INMT, AANAT, IDO2 | MDM2 90/4885MDM4 1192/4885TP53 401/4885 |
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | MDM2 938/4885MDM4 1827/4885TP53 130/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MDM2 3730/4885MDM4 934/4885TP53 3426/4885 |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | PSMC1, PSME3, PSMA6 | MDM2 161/4885MDM4 1440/4885TP53 595/4885 |
| US-20240360178-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM2 757/4885MDM4 1128/4885TP53 158/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM2 765/4885MDM4 1149/4885TP53 154/4885 |
| US-11566057-B2 | Long-acting co-agonists of the glucagon and GLP-1 receptors | GLP1R, GCGR, GIPR | MDM2 4682/4885MDM4 4849/4885TP53 4777/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM2 423/4885MDM4 1648/4885TP53 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.